An observational study in Esophageal Squamous Cell Carcinoma (ESCC), Infiltration and Tumour, sponsored by Shanghai Chest Hospital. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Shanghai Chest Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital — 7 open to participants now, 7 under way, none of them phase 3. Esophageal Squamous Cell Carcinoma · Shanghai Chest Hospital.
Among the 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →7 of the 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Chest Hospital · Sites in China
Ages 18+
Shanghai Chest Hospital · Sites in China
Ages 20–75
Shanghai Chest Hospital · Sites in China
Ages 18–75
Shanghai Chest Hospital · Sites in China
Ages 18+
Shanghai Chest Hospital
Ages 18–75
By country, each count listing its studies:
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10
First in 2019; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 225 across 88 observational studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 51 across the 10 interventional studies, 115 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Chest Hospital is the lead sponsor of 198 studies on the registry; 99 are open to participants now.
1 of the studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05978193Shanghai Chest HospitalRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
Patients with c/ycT2-3 esophageal squamous cell carcinoma (ESCC) who underwent McKeown esophagectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Receive esophagectomy for treatment
Other: Esophagectomy · Procedure: Esophagectomy
Esophagectomy by McKeown method
Esophagectomy for ESCC
Infiltration pattern
Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.
Time frame: Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.
Plan to share: No
Ran from Oct 2025 to primary completion in Apr 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →